Tuesday, August 13, 2019

Very Brief Blog: Association of Molecular Pathology's Elaborate Position Statements Page

The Association of Molecular Pathology (AMP) has a long record of producing active, detailed policy statements and position letters, some on its own, some in collaboration with other groups (such as College of American Pathologists, CAP). 

It's worth checking out form time to time, and the webpage is in a clear and accessible format.

  • Find the open access AMP policy page here.
Just a few of the recent comments on that webpage include:
  • July 25:  Opposition to Patent Reform Legislation; see also June 3
  • June 20:  Comments on MolDx LCD DL38047 for NGS in myeloid malignancies
  • June 20:  Comments on MolDx LCD DL38045 for NGS in solid tumors
  • June 10:  Position on DTC genetic testing
  • May 29:  Comments on Medicare NCD for NGS Testing in Cancer
  • March 18:  Comments on USPSTF Proposed BRCA Update
  • March 4:  Comments on NCCI Edits for Multiple Tests
The June 20 comments wrestle with MolDx's attempt to craft reasonable policies under some of the poorly written or even ridiculous aspects of the CMS NCD on NGS testing.   After much protest in early 2019 (see trade journal articles and AMP's February 1 letter to CMS), CMS took a comment period May 29-April 29 on how the NCD could be revised.  CMS will issue proposed revisions for another round of public comment by October 29.


In solid tumors, the CMS NCD covers an NGS test only if it has not been used before in the same primary diagnosis of cancer...that sounds like coverage x1.   AMP/CAP note that when tumors are relapsed, recurrent, or simply metastatic, they often show gains and losses in mutations, "rendering them, in effect, new cancers."   MolDx may have been thinking this too, since it seemed to narrow the CMS instruction to apply only to tests performed "on the same tumor specimen." 

On the other hand, the LCD might seem to provide coverage more narrow than the NCD (a scenario which is not allowed), since the NCD covers "any FDA approved NGS test" as long as it has not been performed before.  Seemingly the NCD might be read to allow two different FDA NGS tests to be performed on the same specimen, since, simply, neither has been performed before.  While the LCD says that a CGP (comprehensive genomic profiling) test won't be allowed if another CGP has been performed on the case.  Technical!

AMP Meetings

AMP's annual meeting will be November 7-9, 2019, in Baltimore.  Here.  It looks like registration is $675 member, $850 non-member.  (That's a $175 delta; for $200 you can become a member, so a net cost of $25 if you're going to the meeting anyway).

AMP will also host a "Molecular Pathology Economics Summit" in Washington, Friday, September 20, 2019.  Here.  It look like registration is $975 for for-profit organizations, $375 for non-profit. The preliminary agenda is online here.




Monday, August 12, 2019

Close Up View: Proposed Changes to Molecular Test Date of Service Rule

In annual Outpatient Proposed Rulemaking for CY2020, CMS proposed a series of changes to its Date of Service rule, which governs the lines of payment (or non-payment) for tests associated with hospital settings.   Hospital settings include inpatient and outpatient biopsies, but also blood draws taken while patients are visiting a hospital-related Outpatient Clinic.

The whole rule is at 84 Fed Reg 39398ff (August 9, 2019), but I have put the six pages dedicated to Date of Service changes in the cloud here, with light highlighting (e.g. section headings):
  • Find the Seven-Page DOS Rule Proposal Here.
The rule opens with a very detailed history of date of service policy going back nearly twenty years, to 2001.  If you plan to take a Master's Degree multiple choice test on DOS trivia, this is required reading.

Basically, the DOS rule has two aspects - who can bill for the test (the hospital or the performing lab), and whether the test is billable (for example, routine clin chem is now "bundled" to outpatient procedures and outpatient office visits).

In the classic form of the rule, from about 2008-2018, lab tests on outpatient specimens had to be billed by the hospital, if ordered and performed within 14 days of biopsy and blood draw.  If ordered and performed after 14 days (e.g. on a 15 day old paraffin block), they had to be billed by the lab.  In 2018, CMS changed the rules so that human genomic tests (and ADLT tests) could be billed immediately by the laboratory.*

However, as CMS explains in this rulemaking, due to industry complaints, CMS has delayed implementation of the new rule for a total of two years (most recent delay is through January 2020).   So right now, either hospital or genomic lab can bill for a human genomic test on a hospital outpatient biopsy or blood draw.  CMS DOS website here.

CMS is probably uncomfortable with this ambiguity about who will bill, and they propose three options (p. 39601):
(1) Change or unwind the new rule, (2) narrow the new rule only to ADLT tests, and if the rule is implemented (the lab must bill), or (3) then make an exception for blood bank labs, which only want to bill via the originating hospital and never directly to CMS.

Comment is open til September 27, 2019.  Fed Reg webpage here, comment page here.




___

* Most ADLT tests are also human genomic tests.  However, a protein-based ADLT test would be an example of an ADLT that is not also a human genomic test.






Thumbnail Summary: New Policy Themes for Breakthrough Devices

UPDATE: CMS finally published a Breakthrough rule in August 2020 - here.

_____

There have been a number of Medicare health policy changes, or proposed changes, for Breakthrough Devices in the last couple years, and I provide an inventory of major sources here.

  • (1) EXCITE and PACER (2016/2017)
    • In 2016, 2017 there was an industry proposal called PACER - Provisional Accelerated Coverage to Encourage Research.
    • National Academy of Sciences produced a 16-page white paper in 2016
    • In 2017, CMS proposed a similar idea called EXCITE - Expedited Review of Innovation Technology.
    • For example, Jeff Shuren of FDA referred to unnamed CMS-FDA programs in preparation at JP Morgan January 2018.
    • For links to all the above, see a February 2018 blog here.
  • (2) AdvaMed/HR 5997.  In 2018, Advamed strongly supported a bill to encourage access to breakthrough products in the Medicare system - H.R. 5997 (sponsored by Delbene).  
    • See a November 2018 blog about HR 5997 here.
    • While HR 5997 expired with the old Congress, it could reappear in similar form in 2019.
  • (3) 2019 LCD Changes.  In October 2018, CMS released new processes for LCD creation, public LCD requests, and LCD revisions, effective for CY2019.  
    • For example, CAC (advisory) meetings were made optional.  CMS touted this as an important for speeding up the LCD process, but frankly, I didn't see it then and I haven't seen it yet (through August 2019).   For an October 2018 blog on LCD changes, and CMS press releases, here.
  • (4) May 2019 Verma Speech.  Seema Verma gave a major speech to the Medical Device Manufacturers Association (MDMA) on plans to encourage new technology - transcript here.  See also my discussion here.
  • (5) August 2019 Inpatient Final Rulemaking - Perks for Breakthrough Devices.  New inpatient technologies can get an extra add-on payment over the DRG - called NTAP - if they jump several hurdles.  In August 2019 rulemaking, CMS somewhat expedited the process if a device had been classified as Breakthrough by the FDA.   
    • Links and entry points, here.
    • Not only did CMS make these tweaks to NTAP, but CMS strongly highlighted their importance in the accompanying hospital rule press release (see Links entry point).
    • FDA page for Breakthrough Devices, here.  FDA final guidance (30pp) here.
  • (6) Pending CMS/FDA Breakthrough Rule at OMB.   Since September 2019, a rule "CMS 3372 P" has been pending at OMB.  As of August 2019, it's still pending.  The rule is "Medicare Coverage for Innovative Technologies."  One theory is that CMS wanted the FY2020 inpatient rule to be finalized in August 2019, so it can incorporate background and cross-references in the 3372 rule.   
    • I provide some background and links on CMS 3372 P here.  
    • (Note, this is the same blog from November 2018 in which I discussed HR 5997.)

Take home lesson - the next big thing to watch will be the release of CMS 3372 P, which will be the third or fourth generation of ideas that started in 2016 with PACER.  But -- From available information, I can't completely rule out that 3372-P might be a false lead, an orphan fragment of rulemaking, and simply reflected inpatient rulemaking that has now been completed inside the August 2019 final inpatient rule.  But 3372 P,as a draft proposed rule placeholder, is alive and online here.

Footnote.  Although not a breakthrough device, in a recent final NCD markedly simplifying access to CAR-T therapies, CMS emphasized its dedication to getting new technologies to Medicare patients quickly - here.

Thursday, August 8, 2019

CMS Posts Summer CLFS Meeting Videos; Posts Expert Panel Price Proposals for New Codes

Videos!

CMS has posted videos from its three days of summer meetings on how to price new lab codes for CY2020.   90 codes were under review and public comment.    June 24, 2019, was a public comment meeting.  July 22-23, 2019, was an expert panel meeting.

CMS did not post any of these videos for the Summer 2018 cycle a year ago, but responded to community requests to archive the videos of these webcasts.

CMS VIDEO PUBLIC COMMENT


CMS VIDEO EXPERT PANEL
0722 AM
0722 PM
0723 / AM
0723 PM


Votes !

CMS also posted the voting results of its advisory panel meeting.   See the home page here, see the full 90 page of results PDF here.

Panelists voted in 100% agreement 49 times, and another 12 times they were in greater than 90% agreement.  So 61 times out of 90, the panel agreed >90% one a single choice.

On the other hand, there were 12 votes with the highest ranked choice 70-89%, and 11 votes with the highest ranked choice 50-69%.   6 votes especially widely split, with the highest ranked choice < 50%.

By my tally, there were 28 codes out of 90 where the highest-ranked choice was Gapfill, of which half or 14 were unanimous.  IN one particularly split vote, the highest ranked choice was gapfill at 38% (code 0128U).

Wednesday, August 7, 2019

CMS Drops CED from CAR-T Coverage; Covers FDA Label and NCCN Indications

On February 15, 2019, CMS released a draft coverage policy for CAR-T therapies, which would have required elaborate Coverage with Evidence Development restrictions (here, here).  The NCD was targeted for finalization on May 16, 2019, but CMS delayed the finalization indefinitely via a brief press release (here).

On August 7, almost three months delayed, CMS released a final NCD (press release here, NCD here.)



Most notably, the decisional part of the NCD has been shortened from 1800 words to only 150 words. 

CAR-T therapies will be covered on FDA indications and compendium (e.g. NCCN) endorsed indications.   This essentially minimizes the role of this NCD as an impactful coverage document, since major cancer drugs would generally be covered on FDA indications and NCCN indications by local contractors (MACs) anyway. 

Compendia

Criteria for cancer compendia indications were established by CMS regulation 42 CFR 414.930, 2009.   Specific compendia at any given time are updated regularly by CMS in program documents.  Based on current program documents (here), at 50.4.5, NCCN indications I and 2A are always medically accepted; NCCN 3 is not accepted; I believe NCCN 2B is at discretion.

Trade Journals

  • The first CAR-T approval was in mid 2017 (here).
  • Boston STAT here.
  • WaPo here.
  • BioSpace here.
  • MedCity News here.
  • EndPoints here.
  • ASCO Post here.
  • American Society of Hematology press release here.


Press Release Provided by CMS

The press release is titled, "Trump Administration Makes CAR T-Cell Cancer Therapy Available to Medicare Beneficiaries Nationwide."   Opening, "the Centers for Medicare & Medicaid Services (CMS), under the leadership of President Trump and Secretary Azar, finalized the decision to cover FDA-approved Chimeric Antigen Receptor T-cell, or “CAR T-cell” therapy, which is a form of cancer treatment..."  (On the rising use of President Trump's name in routine Medicare press releases, here.)

In contrast, a very recent press release regarding an NCD on acupuncture in back pain made no reference to either Pres. Trump or Secr. Azar (here).

Monday, August 5, 2019

Perspective: The Coordinated Roll-out of New Kidney Care Plans by Trump Administration

Update 2025: 
Abe Sutton (McKinsey, White House, Harvard Law, Rubicon) may be head of CMMI under the 2025 administration.

### 
August 2019:

The "Mainstream Media" e.g. Bloomberg, has sometimes criticized the Trump administration for "scattershot and at times contradictory" handling of health policy (here).

In contrast, there was a thoroughly planned and quite well-coordinated roll-out of broad sets of plans to improve renal care under CMS, across the prevention, dialysis, and transplant levels.   This occurred around July 10, so we can look back now with some perspective.



Azar Addresses National Kidney Foundation (April 2019)

In April, Secretary Alex Azar gave a detailed speech to the National Kidney Foundation (online here).   He focuses on renal disease as one of the areas of long-accumulated policy failures and an issue the Trump administration wants to address.  He highlighted the long transplant waiting lists, the burdens and morbidity of dialysis, and the lack of home dialysis in the U.S.  (He compared our home dialysis rates to Hong Kong and Guatemala, both of which do better).  He highlighted the public private partnership of KidneyX, designed to speed the creation of wearable or implantable dialysis options.

He concludes by noting, "We just need renewed ambition and the right policies. President Trump has the kind of ambition we need to deliver much better care for Americans, even if it means bold change."

July 10, 2019, Program Roll-Out

The program roll-out was complex and well-coordinated, with numerous documents springing up online, from White House to HHS to CMS.

White House

  • The president gave a speech, including several brief speakers with personal or family kidney problems.
    • Full speech here at Youtube here.
    • See in particular an edit for the President's remarks, here.
    • The level of enthusiasm the President brings to the speech and participants is palpable. 
    • While there are certainly sections based on the teleprompter, there is an interesting digression where he talks about his Administration's efforts on Right-to-Try laws, which I've seen him spontaneously mention before.
  • See also the White House Press Release here.
  • See also the White House Executive Order here.
  • See also the video remarks full transcript here.
Health and Human Services
  • HHS had its own press release, here.
  • The Assistant Secretary For Planning & Evaluation office created a home page for ESRD initiatives.
    • ESRD ASPE Home Page here.
    • ASPE 42-page white on ESRD policy work, projects, and vision, here.
  • See also HHS documents on KidneyX:
    • Press release here.
    • KidneyX home page here.
    • 2018 launch of KidneyX press release here.
CMS Press Sources
  • CMS had a press release here.
  • CMS had a press release about the mandatory CMMI demonstration project here.
  • CMS had a press release about the voluntary CMMI demonstration project here.
CMS/CMMI Treatment Choices Models

Within CMS, CMMI (led by Adam Boehler) had its own webpage and documents: here,
The Federal Register official publication was pre-released for July 10 and formally published on July 18:
  • 84 Fed Reg 34478-34595 (118 pages) here.
    • PDF here.
    • Comment open til September 16, 2019.
 I've put key documents like the CMMI rule and the Executive Order and most press releases in one cloud zip file here.   My point is that the above reflects a monumental amount of effort and coordination and the launch was highly organized over the different executive divisions.   While a recent 300-page book highly critical of the current Cabinet was recently published, the book had essentially not one critical word to say about HHS (except some a couple references to Tom Price's air travels in 2017).

Trade Press Coverage

Trade press coverage was generally favorable.
  • Health Payer Intelligence here.
  • Roll Call here.
  • JDSupra, Faegre Baker Daniels, here.
  • Renal Physicians Association here.
  • Becker Hospital Review here.
  • Modern Healthcare here.
  • Healthcare Dive here.
  • Politico here.
  • Marketwatch here.
  • From September 2019, see two articles in JAMA here and here.

General Press Coverage

General press coverage was also generally favorable.
  • NYT here.
  • WSJ here.
  • WaPo here.
  • CNN here.
  • NPR here.
  • Forbes here and here.
  • CNBC here.
    • CNBC follow-up; renal stocks rise, here.
  • Fox News here.
  • LA Times here.
    • Noting that CMMI ESRD program is tied to ACA which is under court threat, as a whole.
  • In the next week, there was also coverage of CVS moving toward home dialysis with new technologies, here and here, at Bloomberg and Healthcare Dive, respectively.
  • A little further afield, see favorable press as diverse as Breitbart here, and Al-Jazeera here.


Summary

Overall, this was a very impressive roll-out, especially when you consider the relatively hostile media environment and the fact that the roll-out of anything is ten (or a hundred) times harder than it looks on the surface.

Another point is that this Administration often flags what will happen 3-6 months in advance.  Even for people far outside the Beltway, the April 2019 speech by Azar (which I opened with) flagged most of the emphasis points for the ESRD roll-out in July.  Similarly, speeches by Joe Grogan and Seema Verma early in the year (blog here, links to full text therein) flagged themes on out-of-network payments and price transparency (Grogan) and CMS's new approaches to breakthrough technology (Verma) that would burst into wider attention in the summer.

Any reservations?  Maybe a few.  There are a few bullets in the Executive Order that seem superfluous - "FDA shall accept PMA applications for artificial kidneys..." - I'm pretty FDA would do that with or without an E.O. bullet point.  And my sense, as an outsider, is that a lot of really smart organizations and experts already work full time and really hard on donor allocation (e.g. one entry point here, but there are many).  But good luck to them on the implementation work ahead.


___

A key policymaker for ESRD and other recent efforts was Abe Sutton, a millennial and McKinsey graduate, who leaves White House for law school in August 2019 - here.  He was part of the Domestic Policy Council from the first Trump year, 2017, until now, rising to be head of health policy for the DPC.
___

In JULY, the big theme in healthcare was ESRD.   In JUNE, it had been payment transparency and out of network billing, here.  In AUGUST, one big theme is Antibiotics policy, here.   

___

For an August 25, 2019, Los Angeles Times expose' of money and politics in the dialysis industry, here.    For an August 26, 2019, WSJ Op Ed on liver transplant policy and incentives, here.   For an August 26 news story and JAMA Internal Medicine on US rates of donor kidney wastage, here, here, here.

For September 2019 JAMA articles on dialysis ownership vs results, here and here.
   For a 2018 article on current state incentives for organ donation, Levy, here.
   For a November 2019 JAMA perspective on Trump proposals, Thomas et al, here.

For a September 2019 trade journal view on reactions to the Trump plan, here.

CMS dropped rulemaking for organ procurement and distribution in December 2019, here.







Very Brief Blog: CMS Leadership Highlights Initiatives for Antibiotic Crisis

Somewhat buried in August 2 Friday night inpatient rulemaking, but highlighted separately in a Health Affairs blog by Seema Verma and a summary at Endpoints... New administration inititatives for the antibiotic crisis.

This weekend, concurrent, the CEO of Novartis interviewed in NYT about the global antibiotic crisis - here.
  • Seema Verma blog Health Affairs here.
  • See also Seema Verma's August 6 "Tweetorial" on Abx policy, here.
  • Coverage at Endpoints here.
PEW Charitable Trusts has long taken a public policy lead role on this issue (here), and urged CMS to finalize the ASP rulemaking for hospitals as long ago as November 2018 (here).  IDSA also strongly supports ASP requirements for hospitals (here).  The President's Advisory Council on antibiotic resistance (PAC-CARB) in April 2019 urged CMS to finalize hospital ASP rulemaking in the face of the agency's June 2019 deadline (here).

Finally, to the relief of many stakeholders, in June 2019, CMS extended the imminent deadline for action one year forwards, to June 2020 (here).

Opening the August 2 blog:
The Centers for Medicare & Medicaid Services (CMS) under the Trump Administration has been committed to unleashing medical innovation, with notable policy initiatives including a revolution in interoperability, the expedited approval of transformative new technologies, and the creation of new authority for payment for telehealth benefits for patients in traditional Medicare and Medicare Advantage. 
Antimicrobial resistance (AMR), which affects millions of Americans and results in thousands of deaths annually, is an ongoing public health crisis where CMS is leading the way to remove regulatory barriers and payment disincentives to innovation. In this post, I will outline the agency’s multi-pronged strategy for stimulating access to antibiotic innovation through the Fiscal Year (FY) 2020 Inpatient Prospective Payment System (IPPS) rule, including changes to the New Technology Add-On Payment and severity adjustments to ICD-10 codes for AMR. I will also discuss CMS’s interest in addressing AMR beyond payment reform, such as investments in public health infrastructure like stewardship programs. 

For uses of "Trump Administration" and "Vision of President Trump" in recent CMS press, here.

Specific to Antibiotic Stewardship for hospitals, which HHS proposed in 2016, and extended completion from 2019 to 2020, Verma writes:
While the proposed actions listed above are necessary to fill in the missing market for new antibiotics designed for resistant pathogens, CMS also recognizes the vital importance of going beyond payment reforms and investing in public health infrastructure to slow the development of resistance to existing drugs.
One strategy recommended to the agency by stakeholders during the public comment period on the proposed FY 2020 IPPS rule was regulation for Antibiotic Stewardship Programs. Although stewardship lies outside of the scope of rulemaking for this year’s IPPS, the agency appreciates the feedback from the clinical community. CMS has long been supportive of efforts to address the public health challenge of AMR via clinical guidelines; we already require the implementation of Antibiotic Stewardship Programs at different sites of care (such as long-term care facilities). 

CMS is currently reviewing approaches for implementing guidelines for hospital-based Antibiotic Stewardship Programs via the regulations that govern hospitals’ Conditions of Participation in Medicare. This would provide an avenue for the agency to build on the payment reforms implemented through IPPS, create consistency with parallel actions from our partners (e.g., the Joint Commission’s recently announced stewardship requirements for outpatient facilities), and significantly enhance the safety of Medicare beneficiaries during inpatient stays. The agency also recognizes -- as highlighted by significant stakeholder feedback -- that stewardship programs are necessary to reinforce the effectiveness of payment reforms;  stewardship should steer clinicians towards the appropriate use of new antibiotics, which may include antibiotics designated as QIDPs.

CMS’s Commitment To Addressing AMR 
AMR is both a public health crisis and a national security imperative that demands systemic policy action. CMS is committed to ensuring that its policies support the pipeline of drug development and enable Medicare beneficiaries and all Americans to access life-saving medicines. The removal of disincentives for innovation in the final FY 2020 IPPS rule should pave the way from bench to bedside for new antibiotics, while the agency’s parallel action on stewardship and consideration of DRG redesign should lay the groundwork for future policy action.


____

Entry point to this blog from Linked In, here.

Friday, August 2, 2019

Very Brief Blog: CMS Publishes Final Inpatient Rule FY2020; New Tech Addon for T2 Pathogen Test

On August 2, 2019, CMS has published the final inpatient (IPPS) rule for FY2020.
  • Final rule Federal Register homepage here.
  • Early-edition (inspection copy) of rule, here.
    • Typeset Fed Reg publication August 16.
T2 Wins NTAP

CMS granted New Technology Add-On Payment status (NTAP) to the T2 Bacteria Panel, a molecular test for rapid pathogen identification in sepsis.   Discussion, which is pretty grueling, having to block and tackle many CMS concerns, is at page 695-725.  The add-on payment is capped at $97.

In other infectious disease news, some inpatient antibiotics also met NTAP criteria.

NTAP Rulebook Updated

CMS published and finalized some very lengthy policy initiatives for the New Tech review process, most notably, FDA Breakthrough Devices will automatically meet the "substantial clinical improvement" criterion for NTAP.  (726ff).  

New Breakthrough Rule About to Break Through

Entirely separate from this IPPS final rule, on August 2, some trade journal sources noted that a CMS rulemaking on other ways of handling Breakthrough Devices was at OMB review awaiting release.  In fact, CMS and FDA have been discussing such a Breakthrough rule for a couple of years now.

No Change for CAR-T

CMS raised the NTAP percent payment from 50% to 65% in general, and 75% for certain new FDA approved antibiotics (QIDPs).

However, despite what was likely a mountain of comments, CMS makes no change to CAR-T policy.

___

More on T2.

Overall, T2 Biosystems shares have slipped from $23 to 60 cents over five years. Market cap is about $27M, about the same as cash-on-hand.  The stock was down 50% this week on weak revenue growth, independent to the after-market release of the CMS NTAP news.

___

See the press release on the Final IPPS rule, here.   For discussion of citations of President Trump by name in the materials, here.

Thursday, August 1, 2019

Myriad Genesight Garners United Health Coverage; Stock Spikes Upward

On August 1, 2019, Myriad issued an SEC filing that it had garnered coverage from United Healthcare for its Genesight test.

Share price spiked from $29 to $44, with a peak market cap of $3.8B, up 50% from yesterday.

click to enlarge
See:

  • Coverage at Genomeweb here.
  • Myriad's SEC filing here.
  • Actual United PDF Policy for October 2019 here.
  • Update: MedTechDive on how payers are reacting, 8/27/2019, here.
Readers are directed to the actual United Healthcare policy.   It's for treatment-resistant depression defined as one drug failure, a diagnosis of major depressive disorder (or anxiety), and for panels with "no more than 15 relevant genes."    At least on first reading, it does not appear to require prescription by a psychiatrist.  (Psychiatrist's care and test order has been a requirement for Medicare's coverage of Genesight.)

The decision is paired with some non-coverage features, such as non-coverage remarks for other Myriad Genesight panels (for ADHD, for example) and non-coverage for panels with other PGx indications like cardiovascular or polypharmacy.   

As far as I can tell on first reading, it doesn't specifically cover Genesight alone, but may be valid coverage for similar PGx panels (e.g. Althea NeuroIDgenetix, with a favorable discussion of its large RCT Bradley trial).   Some decisions regarding the various marketed alternatives in the field may be left to in- or out-of-network contracting, or other factors outside the text of the policy.




___

Myriad's brief SEC filing states:

UnitedHealthcare has issued a positive coverage decision for pharmacogenetic testing for multi-gene panels including the company’s GeneSight Psychotropic test.  The coverage is for patients that have a diagnosis of major depressive disorder or anxiety and have failed at least one prior medication to treat their condition. The positive coverage decision is referenced in the UnitedHealthcare August 2019 Network Bulletin.


___

In the first version of this blog, I misread and excluded "anxiety" in my text, although it was present in the quotation.

Wednesday, July 31, 2019

Very Brief Blog: ACLA vs PAMA: It's Alive!!

A 3-judge panel in Washington has revived the ACLA's lawsuit against CMS and PAMA regulations, remanding the case back to the lower court for further decisions.

In October 2018, the case was decided negatively in federal court on the grounds that while ACLA had standing as a litigant, PAMA law shielded CMS price setting from judicial review.  Here, here.

Oral arguments on appeal were heard in April 2019 (here, here).    In parallel, a few weeks ago, a bill to delay and revamp the PAMA process was introduced in Congress (here).

On July 31, Appeals Court ruled that whenever a Congressional bar to judicial review is encountered, it should be interpreted as narrowly as possible.   While the court acknowledged that (as the lower court had done) the judicial review prohibition written into PAMA might be interpreted to apply both to the PAMA rulemaking process and the PAMA pricing process, this would not be the narrowest interpretation.
My sense reading the case (as a non-attorney) was that the Appeals Court was also skeptical of applying the bar to judicial review to notice-and-comment rulemaking, because then, a mischievous agency could run roughshod over notice and comment rulemaking, making all kinds of mistakes, and there would be no recourse to court.
Net-net, the Appeals Court decided that the notice-and-rulemaking phase of PAMA pricing was separable from the actual triennial pricing process, and that the former could be judicially reviewed, although Congress had barred the latter from review.

  • See coverage of the decision at 360Dx here.
  • ACLA press release here.
  • CAP had supported the original case with a brief and issued press release on the win.

Source Document

I've put the full 22 page opinion - which has a very clear overview of PAMA, the issues, and some snappy turns of phrase - in the cloud here.   Written by Judge Cornelia Pillard.  Judge notes that since the case was originally filed in December 2017 (here), CMS has considerably expanded the range of hospital reporting, which was the main point of contention originally.  However, the impact of that is irrelevant to the appellate decision, which simply sends the case back to lower court for the consideration of the facts that was avoided the first time due to the original position on judicial review.





Tuesday, July 30, 2019

Two Offbeat Policy Quirks in Outpatient Rule: Heartflow and Non-Opioid Management

On July 29, 2019, CMS released annual proposed rulemaking for the hospital outpatient and ASC setting, the physician/lab setting, and the ESRD/DME setting (here).  The overwhelming focus of attention was on new proposals that hospitals must publicly post all of their contracted rates with each payer by name (e.g. here). 

There were two quirky zones in the hospital outpatient rulemaking that I'll highlight briefly.  One involves a proposed 50% cut in payment for the digital cardiac technology HeartFlow.  The other involves a lack of movement on CMS's part on better payment status for Exparel, a delayed release anesthetic for surgical pain.

HeartFlow - APC From $1500 to $750?

I summarized HeartFlow's initial battle for payment recognition, and the pathway of CMS rulemaking, in early 2018 here.  (That blog, nerdy in itself, at the bottom links to an even nerdier level of detail and links.)

In brief, CMS initially classed the service as non-payable.  In November 2017 final rulemaking, CMS reversed this non-payment status and placed Heartflow's main code in a $1500 New Technology payment tier.   This was based on invoices or information provided by the public, including the manufacturer.  A few weeks after the November 2017 CMS publication, HeartFlow snagged a $240M funding round.

Now, CMS shows it did not forget this particular story.  CMS found 840 claims from hospitals for HeartFlow in CY2018 (see p 189 ff).   After charge deflation via the cost-to-charge ratio and other math, CMS found a mean hospital cost of $750, so this week it announces plans to put HeartFlow's code in a lower-priced APC, for $750.

How many Heartflow claims came to CMS in CY2018?  This rulemaking states there were 840 claims in the hospital outpatient billing setting.  Sometime between September and November 2019, CMS will release CY2018 data for freestanding Part B claims - here.

Exparel: CMS Pushes Back on Special Payment Status in Outpatient Surgery

In this last couple years, there was been a huge growth of interest in ways to avoid opioid prescriptions.  One of the means is non-opioid pain relief.  For one example, CMS just released a plan to cover acupuncture for lower back pain at least in clinical registry settings (here).

For a couple years, advocates have been urging CMS to cover Exparel with separate payment status in outpatient surgeries.   Exparel is an extended-release formulation of bupivicaine that may reduce the need for post-op opioids. 

In the proposed rule (p 87 ff), CMS discusses why Exparel has been packaged into surgical costs with no extra payment.  CMS states that data analysis showed declining use in the ASC setting, so CMS has made Exparel separately payable there.  CMS does not see declining use in the OPPS setting, and CMS declines to change Exparel's OPPS payment status, although it will be accepting public comment.

I do not have a dog in this fight, but CMS's logic seems fuzzy.  Even flat utilization of Exparel does not show that the pricing policy isn't negative; for example, separately-priced Exparel might have 5x or 10x utilization while helping of patients - you don't know from looking at the current data as the status quo.  (On the other hand, CMS staff may be tracking the occasionally mixed literature, here).

At any case, in responding to the opioid crisis, CMS seemed to bend pretty readily on improving acupuncture coverage, while erecting a wall with regards to Exparel coverage, within a few weeks of each other.

While it's anecdotal, in a July 8 NPR interview, Johns Hopkins professor Travis Rieder describes being in-hospital for severe trauma and postsurgical pain, and that non-opioid formulations were heavily rationed by the hospital due to cost and lack of separate reimbursement.





Monday, July 29, 2019

July 29, 2019: CMS Releases CY2020 PFS, OPPS, and ESRD/DME Rules

On July 20, 2019, several weeks later than normal, CMS issued its annual proposed rulemaking for the PFS (Part B) setting, the hospital outpatient and ASC setting (OPPS), and the annual rulemaking for ESRD and DME.

Below I clip the CMS consolidated brief press release, which contains links to each rule-specific press release and each rule-specific FAQ sheet.    The short press release focuses on Trump administration programs for price transparency, which is just one part of each bundle of policies.

Actual Rulemaking Links
  • OPPS Here .  Fed Reg version August 9, here.  84 Fed Reg 39398-39644
  • PFS Here.   Fed Reg version, August 14, here.  84 Fed Reg 40482-41263.
  • ESRD/DME Here.  Fed Reg version, AAugust 6, here.  84 Fed Reg 38330-38421.
  • The three rules and three fact sheets in a Cloud zip file (50 mb) here.
Hospital Negotiated Rates by Payer

The "big deal" in these rules is in the OPPS rule, requiring hospitals to post negotiated rates by payer by procedure.  There's much ink spilled on this one all over the trade press; for one article on legal aspects here.

DOS
The OPPS rules contain some detailed proposed tweaks to Date of Service rules (p. 667-689).  These include leaving both ADLTs and human molecular pathology tests unbundled, but leaving only the ADLTs exempt from date of service rules.  For example, on first rading, it looks like an Oncotype-type mRNA-based test would be billable, but only by the hospital within 14 days, unless, it gets ADLT status, in which case, it would be billing by the lab.  Whew.  (P. 685-686).

Outpatient Surgery Prior Authorization
Generally, Part A and B fee for service program's don't have prior authorization (outside of a few DME categories.)  CMS proposed Prior Authorization for just a few categories of hospital outpatient services that is apparently sees as high risk of lack of necessity.  These are (a) blepharoplasty (eyelid surgery), (b) botulinum toxin injections, (c) panniculectomy ("tummy tuck" if nonmedical), (d) rhinoplasty, (e) vein ablation (varicose veins; covered if medically necessary.)   Remark "these services are most often considered cosmetic...only covered [in] very rare circumstances."  They state, for example, "panniculectomy services were reported...in combination with procedures performed on the patient's chest region" (p. 39603ff).  See more on Prior Auth rulemaking in a section at the bottom of this blog.

For general entry points in 2018/2019 to a lot of people very aggravated by prior authorization, here.



DME
CMS proposed changes to how DME rates for novel equipment are gapfilled and how these may be revised downward, pp. 146-179; new rules about DME prior authorization (184-208, esp. 203-208), including an acknowledgement of current "overlapping rules and guidance;" and new rules for diabetic strip competitive bidding, 249ff, including changes triggered by the Balance Budget Act of 2018 (253ff; Section 50414 of BBA).

60 Days
Public Comment periods run 60 days, to about September 27, but CMS must finalize the rules by first half of October to meet its November 1 publication deadline (being 60 days before 1/1/2020).
________________________________




CMS Announces Landmark Price Transparency Proposals that Benefit ConsumersAdditional proposed rules Advance Agency’s Patients Over Paperwork and Meaningful Measures Initiatives, Strengthen Quality Incentives, and Build on Commitment to Improving the Lives of Patients with Kidney Disease 

Today, the Centers for Medicare & Medicaid Services (CMS) is announcing three important Medicare proposed payment rules that support the transformation of the healthcare system and deliver on providing quality care for patients.

Calendar Year (CY) 2020 Medicare Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Proposed Rule
This proposed rule contains historic changes as a result of President Trump’s recent Executive Order on price and quality transparency that lays the foundation for a patient-driven healthcare system. CMS is putting forward price transparency requirements that will increase competition among all hospitals by requiring them to make pricing information publicly available. Each year, CMS issues a proposed rule to update CY Medicare payment policies and rates under the OPPS and the ASC Payment System.

For more information, see the following links:


Calendar Year (CY) 2020 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) Proposed Rule
This proposed rule updates payment policies for clinicians paid for the services they provide to Medicare beneficiaries under the PFS and QPP. The proposed policy changes will ensure clinicians spend more time providing high-value care for patients instead of on cumbersome paperwork. As part of CMS’s annual changes to the PFS and QPP, the agency is reducing burden, rewarding clinicians for the time they spend with patients, removing unnecessary measures they have to report, and making it easier for them to be on the path towards value-based care. This proposed rule builds on the Trump Administration’s efforts to establish a patient-driven healthcare system that focuses on better health outcomes.

For more information, see the following links:


Calendar Year (CY) 2020 Medicare End Stage Renal Disease (ESRD) and Durable Medical Equipment Prosthetics, Orthotics, and Supplies (DMEPOS) Proposed Rule

The ESRD and DMEPOS CY 2020 proposed payment rule would update payment policies and rates under the ESRD Prospective Payment System (PPS) for renal dialysis services furnished to beneficiaries and the DMEPOS Competitive Bidding Program (CBP) and Fee Schedule Amounts. This proposed rule puts forth updates to the acute kidney injury (AKI) dialysis payment rate for renal dialysis services furnished by ESRD facilities to individuals with AKI. The proposal would also make changes to the ESRD Quality Incentive Program (QIP), introduce a methodology for calculating fee schedule payment amounts for new DMEPOS items and services, adjustments the fee schedule amounts established using supplier or commercial prices if such prices decrease within five years of establishing the initial fee schedule amounts, and also revises existing policies related to the competitive bidding program for DMEPOS.

For more information, see the following links:


___

Prior Author Additional...

CMS discusses how Prior Auth for surgeries would work (p. 695ff).  Authorization would not be binding on the contractor if later medical review found the services unnecessary.  Getting prior auth would, however, be binding on the surgeon/hospital for any of the listed CPT codes.  Surgeons would be exempt if they have a 90% pass rate.  "CMS or its contractor will review a prior authorization request for compliance with applicable Medicare coverage, coding, and payment rules (new regs proposed at 42 CFR 419.82)."  This suggest MACs might have to have LCDs or articles published for all the codes, to furnish a review standard.  CMS simply states that prior auth cases must provide all documentation necessary to determine compliance on a case by case basis - it would also be hard to submit this without a published guidance.  CMS would give itself 10 days to turn around P.A.  documents.  Upon a denial, a provider may resubmit.   Associated services (e.g. anesthesiology) would also be deniable.  

Data for which US surgeons were top providers of these services would be available by name and address (sorted by CPT code) in a public Medicare database updated through 2017 (here).  CMS makes this download easy, by providing all the relevant CPT codes in Table 38.   AMA and CMS data for 2017 indicate about 2400 cases of the basic panniculectomy code 15830.  However, when I checked that 2017 Part B data for codes 15830, 15847, 15877, there were only a handful of surgeons providing each, collectively having done about 100 cases for 15830, and typically 10-20 per surgeon (this database doesn't show surgeons with <10 cases of any given code).   I may be missing something, but otherwise the 2300 cases must be largely provided by surgeons with <10 Medicare cases per surgeon.

Exact Buys Genomic Health; Market Cap Shifts $1B

Bloomberg reported on Saturday July 27 that Exact Sciences was expected to buy Genomic Health (here).

That was followed on Monday by:

  • Press release, Exact Sciences, here.
  • Article at MedTech Dive, here.
  • Article at Endpoints, here.  Biospace here.
  • Discussion of early stock movements at Yahoo Finance, here.
  • Note, Exact later trended to a value recovery (here), but the dip is still interesting.
As shown in the stock charts above, Exact Sciences was fairly stable last week and dipped about -8% (market cap decrease about -$1B) on Monday July 29.   

Genomic Health began rising last week around July 23/24, scoring a bump of about +20% in a week (market cap increase around +$500M), and +4% on Monday July 29.

Exact shareholders will own about 90% of the new combined company.   The purchase price is only a +5% premium compared to Friday's price for GHDX, but it's about a +20% premium over GHDX's 30-day valuation.

__

In other recent funding news, in the liquid biopsy space, Freenome raised $160M in mid-July, and Thrive raised $110M in May.

___

Interestingly, on the same day, Dark Daily ran an article that FIT may be as good as colonoscopy (here) based on a March 2019 article and Op Ed in Annals of Internal Medicine.

FIT is 82274 $17 or Medicare screening code G0328 ($18; 690,000 uses in CY2017, $14M).  Exact in CY2017 had 230,000 Part B uses for $119M (81528).




Friday, July 26, 2019

AMA's Sudden Unexpected New PLA Code Rules: Once a PLA, Always a PLA?

The AMA holds 3 CPT editorial panel meetings a year, and AMA publishes a summary of actions about a month after each meeting (here).   The most recent summary is from May 2019's meeting in Chicago (here).

At that latter link, see Tabs 53, 54.

In these summaries, AMA panelists voted that if a PLA code (the product represented by the PLA code) is later approved for full-fledged AMA Category I status, it will remain in the PLA appendix but will be tagged with an arrow symbol.   A secondary policy is that if a code is pending as a Category I code, you can't create an interim short term PLA code for it.  You have to just sit tight til the Category I code is published.

click to enlarge


Corresponding text will be published in the 2020 code book, which appears soon, in September/October 2019.

Implications

I tallied the latest 103 PLA codes (including those under consideration for Q32019 now), and estimated that about 25 represent MAAA codes.  These are proprietary tests which, with wide acceptance, would be (or would always have been) eligible to be Category I MAAA codes as numbered as such (815xx).  Now, that won't be possibly if they've already become PLA codes.

So far as I know, an Administrative MAAA code can still be elevated to a Cat I (815XX numbered) code.

Not How Category III Codes Are Treated

PLA codes are rapidly issued codes, as are Category III codes.  However, when a product (service) in Category III codes meets criteria for Category I, the AMA elevates the code to a newly number Category I status.  It does not simply add an arrow-sign to the Category III code

But Wait, There's More: September Policymaking re PLA Revisions

The September 2019 AMA meeting in Seattle will also have some PLA policymaking.  Agenda item deals with new policies for when PLA revisions are allowed versus when a PLA code needs to be deleted and restarted as a new code.

click to enlarge


Finally - Any Barrier Between PLA and Category I Codes Likely a Leaky Barrier

The barrier to be erected between PLA World and Category I numbering seems to be somewhat leaky. 

For example, I tallied about 17 codes of 103 that I estimated could appear in the future as Category I codes as non-branded codes.  For example, let's say one lab gets an early PLA code for gene XYZ.  A couple years later, XYZ is a gene with wide use for several cancer drugs.  So AMP or CAP might create XYZ as a category I code.   It would be a code everyone could use and the original PLA applicant might or might not choose to delete his own code if pricing or coverage were better for the new general-usage XYZ code.